| 摘要 |
The present invention provides safe therapeutic doses of an antagonist of human LIGHT (lymphotoxin-like, exhibits inducible expression and competes with Herpes Virus Glycoprotein D for Herpes Virus Entry Mediator (HVEM), a receptor expressed by T lymphocytes), as well as methods of monitoring whether a therapeutic dose of an anti-LIGHT antagonist is safe. |
